Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial

Abstract Several studies suggest that microbial alterations (dysbiosis) are intimately linked to chronic inflammation occurring upon aging. The aim of this study was to investigate the potential interest of a synbiotic approach (co-administration of a probiotic bacteria and a prebiotic dietary fibre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Audrey M. Neyrinck, Julie Rodriguez, Bernard Taminiau, Camille Amadieu, Florent Herpin, François-André Allaert, Patrice D. Cani, Georges Daube, Laure B. Bindels, Nathalie M. Delzenne
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4713aab700d74803a9b564f44641c02f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4713aab700d74803a9b564f44641c02f
record_format	dspace
spelling	oai:doaj.org-article:4713aab700d74803a9b564f44641c02f2021-12-02T14:16:16ZImprovement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial10.1038/s41598-020-80947-12045-2322https://doaj.org/article/4713aab700d74803a9b564f44641c02f2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80947-1https://doaj.org/toc/2045-2322Abstract Several studies suggest that microbial alterations (dysbiosis) are intimately linked to chronic inflammation occurring upon aging. The aim of this study was to investigate the potential interest of a synbiotic approach (co-administration of a probiotic bacteria and a prebiotic dietary fibre) to improve gastrointestinal wellness and inflammatory markers in middle-aged people. Middle-aged subjects were randomized to take synbiotic (Bifidobacterium animalis lactis and fructo-oligosaccharides (FOS)) or placebo for 30 days. Stool frequency and consistency were improved in both placebo and synbiotic-treated volunteers while the synbiotic treatment significantly decreased the number of days with abdominal discomfort. Synbiotic treatment had no impact on mood dimensions, quality of life scores or the overall composition of the gut microbiota (16S rRNA gene sequencing of DNA extracted from stool). Importantly, plasma proinflammatory cytokines (interleukin (IL)-6, IL-8, IL-17a and interferon-gamma (IFNγ)) were significantly lower after 30 days of synbiotic supplementation. This effect appears to be independent of the gut barrier function. This study demonstrates that a combination of B. animalis lactis and the well-known prebiotic FOS could be a promising synbiotic strategy to decrease inflammatory status with improvement of gut disorders in middle-aged people.Audrey M. NeyrinckJulie RodriguezBernard TaminiauCamille AmadieuFlorent HerpinFrançois-André AllaertPatrice D. CaniGeorges DaubeLaure B. BindelsNathalie M. DelzenneNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Audrey M. Neyrinck Julie Rodriguez Bernard Taminiau Camille Amadieu Florent Herpin François-André Allaert Patrice D. Cani Georges Daube Laure B. Bindels Nathalie M. Delzenne Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial
description	Abstract Several studies suggest that microbial alterations (dysbiosis) are intimately linked to chronic inflammation occurring upon aging. The aim of this study was to investigate the potential interest of a synbiotic approach (co-administration of a probiotic bacteria and a prebiotic dietary fibre) to improve gastrointestinal wellness and inflammatory markers in middle-aged people. Middle-aged subjects were randomized to take synbiotic (Bifidobacterium animalis lactis and fructo-oligosaccharides (FOS)) or placebo for 30 days. Stool frequency and consistency were improved in both placebo and synbiotic-treated volunteers while the synbiotic treatment significantly decreased the number of days with abdominal discomfort. Synbiotic treatment had no impact on mood dimensions, quality of life scores or the overall composition of the gut microbiota (16S rRNA gene sequencing of DNA extracted from stool). Importantly, plasma proinflammatory cytokines (interleukin (IL)-6, IL-8, IL-17a and interferon-gamma (IFNγ)) were significantly lower after 30 days of synbiotic supplementation. This effect appears to be independent of the gut barrier function. This study demonstrates that a combination of B. animalis lactis and the well-known prebiotic FOS could be a promising synbiotic strategy to decrease inflammatory status with improvement of gut disorders in middle-aged people.
format	article
author	Audrey M. Neyrinck Julie Rodriguez Bernard Taminiau Camille Amadieu Florent Herpin François-André Allaert Patrice D. Cani Georges Daube Laure B. Bindels Nathalie M. Delzenne
author_facet	Audrey M. Neyrinck Julie Rodriguez Bernard Taminiau Camille Amadieu Florent Herpin François-André Allaert Patrice D. Cani Georges Daube Laure B. Bindels Nathalie M. Delzenne
author_sort	Audrey M. Neyrinck
title	Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial
title_short	Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial
title_full	Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial
title_fullStr	Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial
title_full_unstemmed	Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial
title_sort	improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4713aab700d74803a9b564f44641c02f
work_keys_str_mv	AT audreymneyrinck improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT julierodriguez improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT bernardtaminiau improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT camilleamadieu improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT florentherpin improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT francoisandreallaert improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT patricedcani improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT georgesdaube improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT laurebbindels improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial AT nathaliemdelzenne improvementofgastrointestinaldiscomfortandinflammatorystatusbyasynbioticinmiddleagedadultsadoubleblindrandomizedplacebocontrolledtrial
_version_	1718391664480878592

Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial

Ejemplares similares